Acute Insulin Response and β-Cell Compensation in Normal Subjects Treated With Olanzapine or Risperidone for 2 Weeks
Response to Jindal
- Thomas A. Hardy, MD, PHD1,
- Adam L. Meyers, MS1,
- Jun Yu, MS2,
- Sudha S. Shankar, MD3,
- Helmut O. Steinberg, MD3 and
- Niels K. Porksen, MD1
- 1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana
- 2MedFocus, Des Plaines, Illinois
- 3Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana
- Address correspondence to Thomas A. Hardy, MD, PHD, Eli Lilly and Company, Lilly Corporate Center, DC 2138, Indianapolis, IN 46285. E-mail: hardyta{at}lilly.com
We recently reported that short-term treatment with olanzapine or risperidone did not impair acute insulin response or β-cell compensation in healthy subjects (1). Dr. Jindal (2) has cited some possible inconsistencies between our study and other reports, which we would like to address.
First, Dr. Jindal notes that our conclusions contrast with those of Ader et al. (3) and points to differences in antipsychotic doses as one possible reason. However, the final olanzapine dose in our study (10 mg/day) is consistent with the package insert's target dose for patients with schizophrenia and also appears to be consistent with common prescribing practices for the treatment of schizophrenia at the time our …
